Trimethylamine N-Oxide in Cardiovascular Disease

A Comprehensive Evidence-Based Review of Causality Versus BiomarqueurUn biomarqueur est un élément mesurable dans l'organisme qui renseigne sur la santé ou la maladie — une valeur de laboratoire, un résultat de scanner, une lecture de la pression artérielle. Association

Editorial note on this revision

This is the second revision. The first corrected accuracy problems found on cross-check against the primary literature—most consequentially, the previous opening statistic (“a méta-analyseUne méta-analyse combine statistiquement les résultats de nombreuses études distinctes en une seule estimation globale. of 44 cohorts comprising over 84,000 individuals… 29% higher CVD risk, 51% higher cardiovascular mortality, 30% higher mortalité toutes causes confonduesLa morbimortalité globale désigne le décès quelle qu'en soit la cause, et pas seulement les maladies cardiaques — le critère d'évaluation le plus large et le plus difficile à fausser qu'une étude puisse mesurer.”), which could not be located in any published meta-analysis and had been attributed to a commercial testing website; it was replaced with verified figures from the three principal meta-analyses (Qi 2018; Schiattarella 2017; Heianza 2017). The reference list was rebuilt around primary, PubMed/PMC-indexed sources.

This revision additionally incorporates an external accuracy audit. Its strongest contributions—adopted here—are the recalibration of the Bradford Hill and NOTEGRADE (Grading of Recommendations, Assessment, Development and Evaluations) est un cadre largement utilisé pour évaluer le degré de certitude des données probantes sous-tendant une découverte clinique, en le classant comme élevé, modéré, faible ou très faible sur la base de facteurs tels que la conception de l'étude, le risque de biais, la cohérence, la directivité et la précision des résultats. judgments (separating the strength of the observational association from the weaker case for causalitéLa causalité signifie qu'une chose fait réellement se produire une autre chose. Elle est différente de la corrélation, qui signifie simplement que deux choses ont tendance à apparaître ensemble.), the restoration of the landmark Tang 2013 NEJM cohort, and tighter epistemic wording distinguishing “no evidence for a large causal effect” from “proof of causalité inverseLa causalité inverse se produit lorsque la flèche va dans l'autre sens : c'est la maladie qui a causé l'exposition plutôt que l'exposition qui a causé la maladie..” A subsequent polish pass added a tiered evidence summary, a renal-function-stratified analysis, an explicit limitations and future-research section, and a balanced account of the divergence in expert interpretation, and completed the migration of every citation to primary, peer-reviewed sources.

Two audit recommendations were declined on verification against primary sources: the proposed change of the γ-butyrobetaine figure from ~1,000-fold to ~50-fold (the ~1,000-fold value is the figure reported by Koeth 2014, Cell Metab), and the request to soften the murine FMO3-knockdown result (“entirely prevents…” is the authors’ own wording in Miao 2015, Nat Commun). Several other audit hedges reflected statistics the audit did not retrieve but that were independently verified here (e.g., the LIRKO >1,000-fold/2.5-fold figures and the Jia 2019 MR effect sizes). Volume/page details in the reference list should still receive a final cross-check before submission.

Biosynthetic Pathways and Meta-Organismal Metabolism of TMAO

The production of circulating trimethylamine N-oxide (TMAOLe TMAO est un composé que vos bactéries intestinales produisent à partir de nutriments présents dans la viande rouge, les œufs et certains poissons. Des taux sanguins plus élevés ont été associés aux maladies cardiaques.) in humans is a multi-organismal process requiring coordinated interaction between dietary intake, the gastrointestinal microbiome, and host hepatic enzymes ^[1,3]. The cascade begins with ingestion of quaternary amine precursors—primarily cholineCholine is a nutrient found in eggs, red meat, and liver. Your body genuinely needs it, especially for the brain., phosphatidylcholine (lecithin), L-carnitineL-carnitine is a compound abundant in red meat that plays a role in fatty acid transport into mitochondria; gut bacteria can convert it through several steps—including the intermediate γ-butyrobetaine—into TMA and ultimately TMAO. The article cites it as the other major dietary precursor studied in TMAO research., and betaine ^[1]. These nutrients are abundant in animal-derived foods such as viande rougeRed meat includes beef, pork, and lamb., egg yolks, and full-fat dairy, although they also serve essential roles in plant cellular membranes ^[1,2].

Once these precursors enter the gastrointestinal tract, a fraction escapes proximal absorption and transits to the distal ileum and cecum, where anaerobic microbiota cleave the carbon–nitrogen bonds of the precursors, releasing the volatile gas trimethylamine (TMA) ^[1]. Choline is converted directly to TMA by the microbial choline TMA-lyase system, encoded by the cutC gene and activated by its partner cutD ^[1].

L-carnitine catabolism follows a more complex, multi-step route mediated by distinct bacterial intermediates ^[2,4]. L-carnitine is first converted by gut bacteria to γ-butyrobétaïne (γBB)La γ-butyrobétaïne (γBB) est un intermédiaire métabolique majeur formé dans l'intestin proximal lorsque les bactéries commencent à transformer la L-carnitine alimentaire ; elle s'accumule à un taux environ 1 000 fois supérieur à celui de la formation directe de TMA et agit comme un réservoir qui soutient la production de TMA et de TMAO bien après qu'un repas contenant de la viande a été digéré.; the canonical carnitineCarnitine is a nutrient found mostly in red meat. Your body also makes some on its own. monooxygenase (cntA/B) is oxygen-requiring and is therefore unlikely to be the dominant route in the largely anoxic colonic lumensLe lumen est le canal ouvert à l'intérieur d'un vaisseau sanguin par lequel le sang circule réellement., where an anaerobic γBB pathway predominates ^[4,5]. In isotope-tracer and mouse-intestinal incubation studies, γBB is generated at a rate roughly 1,000-fold higher than direct TMA formation and is the major gut-microbial metabolite of dietary L-carnitine; it is either absorbed into the systemic circulation—where it can act as an independent proatherogenic intermediate—or further metabolized by distinct anaerobes through crotonobetaine to TMA ^[4,5].

Newly synthesized TMA is lipophilic and diffuses across the intestinal mucosa into the portal circulation, which delivers it to the liver ^[3]. In hepatocytes, TMA is oxidized to the odorless, water-soluble TMAO, a reaction catalyzed by the flavin-containing monooxygenase (FMO) family, principally the FMO3 isoform—the most abundant and active FMO in the adult human liver ^[6,7].

Under normal physiological conditions, systemic TMAO is distributed throughout the extracellular fluid and cleared chiefly by the kidneys, with filtration glomérulaireGlomerular filtration is the process by which the kidney's glomeruli — tiny capillary networks — filter waste products and small molecules, including TMAO, from the bloodstream into the urine; adequate glomerular filtration clears fish-derived TMAO within roughly 24 hours, whereas chronic kidney disease reduces this clearance and allows TMAO to accumulate. as the dominant elimination route ^[3,18]. Renal clearance is therefore the single most important determinant of steady-state plasma concentrations in individuals with preserved kidney function ^[18,19].

Hepatic FMO3, Insulin Resistance, and Metabolic Syndrome

FMO3 is a metabolic hub linking the microbiote intestinalThe gut microbiome is the enormous community of bacteria living in your intestines. There are trillions of them, and they are not passive passengers., host lipid transport, and systemic energy homeostasis ^[7,8]. Hepatic Fmo3 expression is under hormonal control: in insulin-sensitive states, insulineL'insuline est une hormone produite par votre pancréas. Son rôle principal est de permettre au sucre de quitter votre sang pour pénétrer dans vos cellules afin de servir de carburant. suppresses Fmo3 transcription, whereas glucagon and glucocorticoids stimulate it ^[6,7].

Avec obésitéL'obésité signifie avoir un excès de graisse corporelle suffisant pour nuire à la santé., visceral adiposity, and hepatic résistance à l'insulineLa résistance à l'insuline se produit lorsque vos cellules cessent de bien réagir à l'insuline, ce qui oblige votre pancréas à en produire de plus en plus pour faire le même travail., this suppression is lost ^[7,8]. Chronic free-fatty-acid oversupply drives diacylglycerol accumulation and PKC-epsilon activation, which impairs hepatic insulin-receptor signaling; because insulin can no longer restrain Fmo3, hepatic FMO3 expression and activity rise ^[7,8].

In liver-specific insulin receptor knockout (LIRKO) mice—a model of selective hepatic insulin resistance—TMAO was the most strongly upregulated of 175 profiled hepatic metabolites, Fmo3 was the second most highly upregulated transcript, with a greater-than-1,000-fold increase in hepatic Fmo3 mRNA accompanied by an approximately 2.5-fold increase in plasma TMAO relative to controls ^[7]. In primary hepatocytes, insulin repressed and glucagon elevated FMO3 expression, and hepatic FMO3 mRNA was higher in heavily obese, hyperglycemic patients than in leaner, normoglycemic controls ^[7,8].

This upregulation is not an inert marker. Antisense knockdown of Fmo3 in insulin-resistant mice suppresses forkhead box protéineLes protéines sont le nutriment que votre corps utilise pour développer et réparer les muscles et les tissus. O1 (FoxO1)—a central node for hepatic gluconeogenesis and lipogenesis—and, in these models, prevents the development of hyperglycémieAbnormally elevated blood glucose concentration; included as one of the modifiable risk factors in the PDAY scoring system because it accelerates arterial lesion progression in adolescents and young adults., hyperlipidemia, and athéroscléroseL'athérosclérose est la maladie à l'origine de la plupart des crises cardiaques et de nombreux accidents vasculaires cérébraux. Des particules de cholestérol se coincent dans la paroi d'une artère, le corps envoie des cellules immunitaires pour nettoyer, et au fil des ans, ce désordre durcit pour former de la plaque. even on a high-fat diet ^[7,8]. Mechanistically, FMO3 influences glucoseLe glucose est le sucre que votre sang transporte pour alimenter vos cellules. and lipid handling partly via reduced lipid-induced endoplasmic-reticulum stress and modulation of SREBP-2SREBP-2 (sterol regulatory element-binding protein 2) is a transcription factor that senses low intracellular sterol levels in the liver and responds by increasing the production and surface expression of LDL receptors, thereby accelerating clearance of LDL from the blood./FoxO1 signaling ^[7,8].

Consequently, in subjects with preserved renal function, plasma TMAO may partly track hepatic sensibilité à l'insulineLa sensibilité à l'insuline est la façon dont vos cellules réagissent à l'insuline. C'est le contraire de la résistance à l'insuline.: when insulin resistance lifts the brake on Fmo3, conversion of gut-derived TMA to systemic TMAO can accelerate ^[7,8]. This mechanism is well supported in murine and hepatocyte systems, and human liver-biopsy data show higher FMO3 expression in obese, hyperglycemic individuals; even so, current human evidence is insufficient to treat circulating TMAO as a validated standalone biomarker of hepatic insulin resistance. The relationship is best stated as mechanistically plausible rather than clinically established ^[7,8].

Causality: Mendelian Randomization Versus Observational Data

Whether TMAO is a direct causal mediator of atherosclerotic maladie cardiovasculaireLes maladies cardiovasculaires sont un terme générique qui désigne les problèmes liés au cœur et aux vaisseaux sanguins, notamment les crises cardiaques, les accidents vasculaires cérébraux et le blocage des artères des jambes. (ASCVD) or a correlative biomarker of metabolic and renal dysfunction is best examined by comparing observational and genetic designs ^[13]. Observational cohorts show a consistent, dose-dependent association between elevated plasma TMAO and événements cardiovasculaires indésirables majeursUn événement cardiovasculaire indésirable majeur, ou MACE (pour *major adverse cardiovascular event*), est un ensemble de mauvais résultats regroupés dans le cadre d'une étude, généralement la décennie cardiovasculaire, l'infarctus du myocarde et l'accident vasculaire cérébral. (MACE) ^[10,11,12]. In the landmark prospective study of 4,007 patients undergoing elective coronary angiography, higher fasting TMAO predicted death, infarctus du myocardeVoir Crise cardiaque pour l'article complet., ou accident vasculaire cérébralUn accident vasculaire cérébral se produit lorsque le flux sanguin vers une partie du cerveau s'arrête, soit en raison d'un blocage, soit d'une hémorragie. over three years, with a rapport des cotesUn rapport des risques instantanés compare la rapidité avec laquelle les événements se produisent dans deux groupes. Un rapport de 0,75 signifie que les événements se sont produits à un rythme égal aux trois quarts dans le groupe traité. of 2.54 for the highest versus lowest quartileOne of four equal groups into which a population is divided when ranked by a measured variable; the article reports that individuals in the lowest fitness quartile had dramatically higher mortality than those in higher quartiles. that remained significant after adjustment for traditional facteurs de risqueUn facteur de risque est quelque chose qui augmente votre probabilité de développer une maladie : des particules de cholestérol élevées, une tension artérielle élevée, le tabagisme, le diabète, des antécédents familiaux. ^[3].

The principal published meta-analyses quantify this association. Qi et al. (2018), pooling 11 cohortes prospectivesUne cohorte prospective recrute des personnes en bonne santé, enregistre leurs caractéristiques, puis attend de voir ce qui se passe., reported a 23% higher risk of cardiovascular events (HR 1.23, 95% CI 1.07–1.42) and a 55% higher risk of all-cause mortality (HR 1.55, 95% CI 1.19–2.02) for higher versus lower TMAO ^[10]. Schiattarella et al. (2017), pooling 17 studies enrolling 26,167 subjects, found high TMAO associated with a 91% higher all-cause mortality (HR 1.91, 95% CI 1.40–2.61) and a 67% higher risk of major adverse cardiovascular and cerebrovascular events (HR 1.67, 95% CI 1.33–2.11), with a relation dose-effetUne relation dose-effet signifie qu'une plus grande quantité de quelque chose produit un effet plus important, selon un gradient constant. of roughly a 7.6% increase in mortality risk per 10 µmol/L increment ^[11]. Heianza et al. (2017) similarly reported elevated TMAO associated with greater MACE (HR 1.41) and all-cause death (HR 1.55) ^[12]. These observational signals are echoed by experimental data: in animal and cellular models, TMAO or its precursors have been shown to promote foam-cell formation, upregulate macrophageUn macrophage est une grande cellule immunitaire qui engloutit les débris et les envahisseurs. Le nom signifie littéralement "grand mangeur"." scavenger receptors (CD36, SR-A), impair transport inverse du cholestérolReverse cholesterol transport is the process of moving cholesterol out of tissues, including artery walls, and back to the liver for disposal. HDL particles do the hauling., and enhance platelet activation and thromboseLa thrombose est un caillot sanguin qui se forme à l'intérieur d'un vaisseau sanguin. ^[2,4,21].

Large-scale Randomisation mendélienneMendelian randomization is a clever research method that uses the genes people were born with as a natural experiment. (MR) challenges the causal interpretation ^[13]. Using single-nucleotide polymorphisms as instruments for lifetime exposure, a bidirectional two-sample MR drawing on DIAGRAM, CARDIoGRAMplusC4D, and the UK BiobankUK Biobank holds detailed genetic, lifestyle, and health data on half a million British volunteers, linked to their medical records. found that genetically predicted higher TMAO and L-carnitine were not associated with maladie coronarienneLa maladie coronarienne est une accumulation de plaque dans les artères qui irriguent le muscle cardiaque., myocardial infarction, stroke, fibrillation auriculaireAtrial fibrillation, often shortened to AFib, is a fast and irregular heartbeat that starts in the upper chambers of the heart., de type 2 diabèteLe diabète est une affection où la glycémie reste trop élevée, soit parce que l'organisme produit trop peu d'insuline, soit parce qu'il cesse de répondre à l'insuline qu'il produit., ou maladie rénale chroniqueLa maladie rénale chronique est une diminution durable de la capacité des reins à filtrer les déchets du sang. after Bonferroni correction (P ≤ 0.0005) ^[13].

The same analysis revealed a reverse-causal direction: genetic liability to type 2 diabetes (β = 0.130 ± 0.036, P < 0.0001) and to chronic maladie rénaleKidney disease means the kidneys have lost some of their ability to filter waste from your blood. (β = 0.483 ± 0.168, P = 0.004) was causally associated with higher circulating TMAO ^[13]. Read carefully, these findings do not establish a large direct causal effect of lifelong higher TMAO on cardiovascular disease; combined with the reverse-direction signals, they are consistent with the authors’ conclusion that much of the observational association may be explained by facteur de confusionLa confusion se produit lorsqu'un troisième facteur caché donne l'impression que deux choses sans rapport sont liées. and reverse causation—a more defensible statement than asserting that every observed association is reverse-caused ^[13].

A separate MR analysis did suggest a possible causal contribution of genetically predicted TMAO and L-carnitine to higher pression artérielle systoliqueLa pression artérielle systolique correspond au chiffre supérieur : la pression dans vos artères lorsque votre cœur se contracte., indicating that while primary athérogenèseAtherogenesis is the step-by-step process of a plaque forming. is not genetically supported, a minor role in vascular remodeling and hypertensive pathology cannot be excluded ^[14].

Systemic Integration of Confounding Factors

Several variables alter both circulating TMAO and cardiovascular risk and account for much of the cross-design discrepancy:

• Renal function (eGFR, cystatin C): glomerular filtration is the primary clearance route, so any reduction in eGFR raises systemic TMAO independent of diet or microbiome activity—making renal function the single largest facteur de confusionA confounder is a variable that is associated with both the exposure being studied (such as TMAO) and the outcome (such as heart disease), making it appear as though one causes the other when a third factor is actually responsible. The article lists renal function, insulin resistance, systemic inflammation, and age as major confounders that inflate the apparent cardiovascular risk of high TMAO in… in observational TMAO studies ^[18,19].
• Insulin sensitivity and syndrome métaboliqueLe syndrome métabolique est un ensemble de cinq problèmes qui ont tendance à aller de pair : un tour de taille important, des triglycérides élevés, un faible taux de HDL, une tension artérielle élevée et une glycémie élevée. En avoir trois ou plus compte.: hepatic insulin resistance upregulates FMO3, accelerating conversion of TMA to TMAO; circulating TMAO may therefore partly reflect hepatic insulin sensitivity, though human validation remains incomplete ^[7,8].
• Systemic inflammationL'inflammation est la réponse de votre système immunitaire à une blessure ou à quelque chose qu'il traite comme un envahisseur. Elle entraîne gonflement, chaleur et cellules de nettoyage.: TMAO correlates with hsCRP and IL-6L'interleukine-6, ou IL-6, est une molécule de signalisation que le système immunitaire utilise pour diffuser un message inflammatoire dans tout le corps., which independently drive remodelage artérielLe remodelage est la façon dont une artère change de forme à mesure que la plaque s'accumule. Souvent, l'artère fait saillie vers l'extérieur pour faire de la place, maintenant l'ouverture au milieu suffisamment large pour que le sang puisse passer. et plaqueLa plaque est une accumulation de cholestérol, de cellules immunitaires, de tissu cicatriciel et de calcium à l'intérieur de la paroi d'une artère. instability ^[20].
• Advancing age: aging lowers GFR and hepatic perfusion and raises rigidité artérielleLa rigidité artérielle est une mesure de la résistance de la paroi d'une artère à l'expansion à chaque pouls sanguin ; elle augmente avec l'âge à mesure que l'élastine se perd et que le collagène s'accumule, et se manifeste cliniquement par une augmentation de la pression artérielle systolique parallèlement à une diminution ou à une stabilité de la pression artérielle diastolique après environ 60 ans., all of which correlate with higher plasma TMAO ^[9,31].
• Microbiome composition: the efficiency of precursor-to-TMA conversion depends on community structure (e.g., relative cutC/cutD and cntA/B carriage), so taxonomic differences shift systemic TMAO ^[1,4].
• Medications and xenobiotics: broad-spectrum antibiotics suppress gut microbiota and abolish TMAO production, but there is no evidence that antibiotic suppression of TMAO translates into improved long-term cardiovascular outcomes (no such trial has been designed to test this); conversely, standard heart-failure therapies improve myocardial strain markers without lowering TMAO, indicating these agents do not act through the TMAO pathway ^[3,21].

Independent Predictive Value and the Renal Confounder

A central question in clinical lipidology is whether TMAO predicts events after adjustment for renal function and traditional risk factors ^[16]. Because TMAO is renally cleared, its prognostic significance depends heavily on how kidney function is handled in multivariable models ^[16,17].

When cohorts adjust for baseline eGFR or cystatin C, the prognostic signal of TMAO is frequently attenuated or abolished. In a large Danish cohort of approximately 1,159 individuals with type 1 diabetes followed for a median of about 15 years, higher plasma TMAO was associated with all-cause and cardiovascular mortality, combined CVD events, coronary outcomes, stroke, heart-failure hospitalization, and end-stage renal disease, independent of conventional risk factors; after further adjustment for baseline eGFR, the associations became non-significant across all endpoints, and TMAO was strongly inversely related to baseline eGFR (R² = 0.29, P < 0.001)—consistent with its prognostic value being largely a function of renal clearance ^[15].

The PREVEND general-population cohort shows the same pattern: among 5,469 participants over a median 8.3 years, TMAO predicted all-cause mortality after risk-factor adjustment (HR 1.36, 95% CI 0.97–1.91), but the association was lost after further adjustment for albuminuria and eGFR (HR 1.15, 95% CI 0.81–1.64), and the TMAO–mortality relationship was significantly modified by renal function (interaction P = 0.002) ^[17].

Community-based cohorts of older adults reinforce this. In the Cardiovascular Health Study, serial TMAO predicted incident and recurrent ASCVD, but further adjustment for eGFR attenuated the recurrent-ASCVD association to non-significance (HR 1.10, 95% CI 0.87–1.39; P-trend = 0.179), and the TMAO signal was concentrated in participants with reduced renal function ^[16]. The companion Multi-Ethnic Study of Atherosclerosis (6,767 adults) likewise found a dose-dependent TMAO–ASCVD association (quintile HRs 1.02, 1.17, 1.23, 1.33) that appeared stronger in those with baseline eGFR below 60 mL/min/1.73 m² ^[16].

These observations support a dual-nature interpretation. In normal renal function and preserved insulin sensitivity, physiological fluctuations in TMAO appear clinically benign—they have not been shown to increase cardiovascular events—and the biomarker behaves as a passenger ^[8]. In moderate-to-severe CKD, however, a vicious uremic cycle—dysbiosis, increased mucosal permeability, and impaired clearance—produces supraphysiological accumulation ^[18,19]. At those concentrations, experimental work links TMAO to inflammasome NLRP3L'inflammasome NLRP3 est un complexe protéique intracellulaire présent dans les cellules immunitaires qui, lorsqu'il est activé par des cristaux de cholestérol, des lipides oxydés ou d'autres signaux de danger au sein d'une plaque athérosclerotique, déclenche la libération des cytokines inflammatoires interleukine-1β et interleukine-6, accélérant ainsi la croissance et l'instabilité de la plaque. activation, TGF-β/Smad3-driven tubulointerstitial fibrosis, and endothelial injury, suggesting a transition from passive marker toward active toxine urémiqueA uremic toxin is a waste product that accumulates to harmful concentrations in the blood when kidney function is severely impaired and cannot clear it adequately; the article describes TMAO as behaving like a uremic toxin only at the very high, 'supraphysiological' levels seen in advanced kidney disease. At normal kidney function it is considered a harmless passenger. in advanced kidney disease ^[19,30].

The strength of the evidence for TMAO pathogenicity therefore varies markedly across the spectrum of renal function, and the two are best kept distinct. With normal renal function, TMAO is chiefly a diet- and microbiome-responsive marker with no demonstrated independent event risk; in mild-to-moderate CKD, concentrations rise as clearance falls and the prognostic association strengthens but remains difficult to disentangle from declining eGFR itself; in advanced CKD and on dialysis, TMAO reaches severalfold-higher concentrations, tracks renal function tightly, and—supported by experimental cardiorenal models—is most plausibly a contributor to, not merely a marker of, cardiorenal pathology ^{[17,18,19,31]}.

Table 5. TMAO across the spectrum of renal function.

Renal status	Typical TMAO	Prognostic association	Best interpretation
Normal (eGFR ≥ 60, no albuminuria)	Low, diet-responsive	Weak/absent after adjustment	Passenger marker of diet and microbiome [16]
Mild–moderate CKD	Progressively elevated	Present but eGFR-entangled	Marker of clearance and disease severity [16,17]
Advanced CKD / dialysis	Severalfold elevated	Strong; tracks renal function	Plausible active contributor to cardiorenal injury [18,19,31]

Dietary Patterns and Post-Challenge Metabolic Kinetics

Long-term diet shapes the capacity to synthesize TMAO. In carnitine- or choline-challenge studies, omnivores generate substantially more TMAO post-ingestion than long-standing vegetarians and vegans, a difference driven by chronic exposure to animal-derived nutrients selecting for TMA-producing taxa ^[5,24]. Suppressing the microbiota with broad-spectrum antibiotics abolishes post-challenge TMAO in both groups, confirming the obligatory microbial step ^[5].

This capacity is reduced but not absent in plant-based eaters: long-term vegetarians can still mount substantial TMAO responses to an oral carnitine challenge ^[24]. In a double-blind randomized pilot, a single lean-vegan-donor fecal microbiota transplant into omnivores with metabolic syndrome shifted recipient microbiota composition but did not alter carnitine- or choline-to-TMAO conversion or arterial-wall inflammation over two weeks, underscoring the resilience of the host metabolic phenotype ^[23].

Table 1. Dietary pattern and TMAO handling (directional summary).

Dietary profile	Fasting plasma TMAO	Post-challenge kinetics (oral carnitine/choline)	Dominant microbiota features	CVD event risk
Vegans	Faible [24]	Flat / minimal TMAO or γBB generation [5,24]	High fiber-fermenting taxa; low cutC/cutD carriage	Lower in observational dietary studies (a dietary-pattern, not a TMAO-specific, finding) [23,24]
Vegetarians	Low–moderate [24]	Intermediate; residual conversion capacity retained [24]	High diversity; variable cutC/cutD and cntA/B	Reduced vs typical omnivores [24]
Omnivores	Modéré [5]	Robust, rapid post-prandial rise in TMAO and γBB [5]	Higher carriage of carnitine/choline-converting taxa	Standard reference [16]
High red-meat consumers	Elevated [2,5]	Large, prolonged post-prandial surges of TMAO and γBB [5]	Enriched carnitine-utilizing pathway [5]	Elevated (matrix-dependent) [16,25]

Plant-rich diets keep baseline and post-prandial TMAO low partly through soluble fibreLes fibres sont la partie des aliments d'origine végétale que votre corps ne peut pas digérer. On les trouve dans les haricots, l'avoine, les légumes, les fruits et les grains entiers. et polyphénolsPolyphenols are a broad class of plant-derived compounds with antioxidant properties; extra virgin olive oil is particularly rich in them, and they are often cited as the reason EVOO may be more protective than refined olive oil, though trials measuring hard cardiovascular endpoints have not confirmed a meaningful clinical benefit.: fiber acts as a prebiotic favoring SCFA-producing taxa and slowing nutrient absorption, while polyphenols appear capable of inhibiting microbial TMA-lyase activity in experimental models ^[5,24]. Whether lower TMAO is itself the mechanism for the reduced cardiovascular risk of régimes à base de plantesUne alimentation à base de plantes, ou à prédominance végétale, est principalement composée de légumes, de fruits, de légumineuses, de grains entiers, de noix et de graines, les aliments d'origine animale étant limités ou absents. is unresolved, because such diets simultaneously lower LDL-C, tension artérielleLa pression artérielle est la force du sang qui pousse contre la paroi de vos artères. Elle s'écrit sous la forme de deux chiffres, comme 120/80. Le chiffre du haut correspond à la pression lorsque votre cœur se contracte, et celui du bas lorsqu'il se relaxe., hsCRP, and body weight—making the independent contribution of TMAO reduction difficult to isolate ^[10,11].

The Fish Consumption Paradox

The strongest empirical challenge to a direct-toxin model is the fish paradox ^[20]. Marine fish accumulate high concentrations of preformed, free TMAO as an osmolyte that stabilizes proteins against pressure, salinity, and urea ^[20]. Because preformed TMAO is absorbed directly without a microbial step, seafood produces rapid, large spikes in plasma and urinary TMAO ^[3].

The magnitude is striking. A cod or halibut meal can raise plasma TMAO several-fold within hours—for example, from a baseline near 9 µmol/L to roughly 23 µmol/L after codfish in one controlled challenge ^[27]—and older dietary studies reported that habitual seafood consumers reach far higher levels than those on egg-and-red-meat diets (on the order of thousands of µmol/L versus low triple digits in the cited pilot data) ^[28]. These excursions exceed those typically achieved on a high-red-meat or egg diet ^[27,28].

If circulating TMAO were a direct driver of atherosclerosis, thrombosis, and arterial inflammation, fish-rich diets should accelerate disease; instead, fish and seafood consumption is consistently associated with reduced maladie coronarienneLa coronaropathie est le rétrécissement ou le blocage des artères qui irriguent le muscle cardiaque, causé par l'accumulation de plaque athéromateuse ; c'est la principale cause de crise cardiaque et de mort cardiaque dans le monde., stroke, mort subite d'origine cardiaqueSudden cardiac death is when the heart abruptly stops and the person dies within minutes, often with no prior warning., and all-cause mortality, and the benefit extends to lean white fish with negligible omega-3 content ^[20]. Several arguments attempt to reconcile the paradox, each with limitations:

• Marine-lipid masking: EPA/DHA anti-inflammatory and anti-arrhythmic effects override TMAO toxicity—but this fails to explain the benefit of lean white fish low in omega-3 ^[20].
• Transient kinetics: seafood-induced spikes are cleared within ~24 h and so are benign, whereas microbial synthesis from red meat is chronic—but habitual seafood eaters maintain chronically elevated baseline TMAO without evident vascular harm ^[20].
• Dysbiosis-marker hypothesis: TMA-derived TMAO is harmful chiefly as a surrogate for a dysbiotic, pro-inflammatory gut microbiome and impaired barrier, whereas seafood-derived TMAO bypasses that microbial step and neither reflects nor induces dysbiosis ^[20].

The fish-feeding literature materially weakens a simple monotonic “higher TMAO equals greater vascular toxicity” model. It does not by itself exclude context-specific effects—for example in acute thrombosis or advanced CKD—but it weighs strongly against circulating TMAO acting as a primary vascular toxin at physiological or moderately elevated human concentrations ^[20].

Red Meat and Cardiovascular Risk: Disentangling TMAO From Alternative Mechanisms

Atherosclerosis is driven by rétention sous-endothélialeSubendothelial retention is the process by which ApoB-containing lipoprotein particles that have crossed the endothelial barrier become electrostatically bound to proteoglycans in the arterial intima and are unable to diffuse back into the bloodstream; it is considered the non-redundant first step in atherosclerosis under the response-to-retention framework. of apolipoprotein-B lipoprotéinesUne lipoprotéine est un tout petit paquet qui transporte les graisses et le cholestérol dans votre circulation sanguine. Comme la graisse ne se dissout pas dans l'eau, elle a besoin d'une enveloppe protéique pour voyager. and recruitment of monocyte-derived cellules spumeusesUne cellule spumeuse est une cellule immunitaire qui a ingéré tellement de cholestérol piégé qu'elle gonfle et prend un aspect écumeux au microscope.. Whether unprocessed red meat accelerates this chiefly through the TMAO pathway or via other mechanisms is unsettled, because red meat carries several bioactive components, each independently linked to vascular injury ^[25].

Table 2. Candidate atherogenic mechanisms of red-meat components.

Composant	Proposed mechanism	Associated biomarkers	Principal modifiers
Saturated fatty acids	Downregulate hepatic Récepteurs des LDLLe récepteur des LDL est un point d'amarrage sur les cellules hépatiques qui capture les particules de LDL dans le sang et les attire pour les décomposer., raising LDL-C/ApoBL'ApoB est une protéine située à la surface de chaque particule de cholestérol susceptible de se coincer dans la paroi de vos artères et de provoquer de la plaque. Chacune de ces particules transporte exactement une ApoB. and arterial-wall retention	LDL-C, ApoB	Replacing SFA with PUFA or plant protein lowers risk [25]
Heme ironThe form of iron bound to hemoglobin and myoglobin in animal tissue, absorbed more efficiently than plant-derived non-heme iron; cited as one of the potentially harmful components of red meat contributing to cardiovascular and cancer risk.	Catalyzes ROS via Fenton chemistry, promoting LDLLe LDL, ou lipoprotéine de basse densité, est la principale particule qui transporte le cholesterol dans votre sang, et la principale qui se coince dans les parois artérielles. peroxidation	LDL oxydéesLes LDL oxydées sont des particules de LDL qui ont été chimiquement altérées après s'être coincées dans la paroi d'une artère., MDA, F2-isoprostanes	Calcium and polyphenols chelate iron, reducing oxidation
Sodium (processed meats)	Endothelial shear stress, arterial stiffness, volume-dependent hypertensionL'hypertension est le terme médical pour la pression artérielle élevée.	Blood pressure, NT-proBNPNT-proBNP (N-terminal pro-B-type natriuretic peptide) is a cardiac biomarker released into the bloodstream when the heart muscle is under mechanical stress or pressure overload; elevated levels in otherwise asymptomatic adults can signal early heart failure or advancing cardiovascular disease before any symptoms appear.	Potassium-rich (DASH) patterns mitigate
Advanced glycation end-products	RAGE engagement activates NF-κB and vascular adhesion molecules	hsCRP, TNF-α, IL-6	Low-temperature cooking reduces AGE formation
L-carnitine / TMAO pathway	Suppresses reverse cholestérolLe cholestérol est une substance cireuse dont votre corps a besoin. Il entre dans la composition des parois cellulaires, des hormones, de la vitamine D et de la bile qui digère vos aliments. Vous en mettriez sans lui. transport; upregulates scavenger receptors	TMAO, γBB, crotonobetaine	Fiber- and polyphenol-rich (Mediterranean) matrix attenuates [5,24]

Although rodent feeding of L-carnitine or choline raises atherosclerosis in a microbiota-dependent manner ^[2], isolating this effect in humans is difficult ^[25]. In randomized trials, the cardiovascular risk of unprocessed red meat depends strongly on the comparison diet: replacing red meat with high-quality plant protein lowers LDL-C and coronary heart disease incidence ^[25]. Notably, incorporating lean unprocessed beef within a Mediterranean-style pattern (rich in acide gras monoinsaturéMonounsaturated fat is the main fat in olive oil, avocados, and most nuts., fiber, and polyphenols) can increase microbiota diversity and lower circulating and urinary TMAO relative to a high-saturated-fat American diet ^[25].

This indicates the proatherogenic potential of red meat is not driven by L-carnitine or TMAO generation in isolation, but by the broader dietary matrix—high graisse saturéeLes graisses saturées sont celles qui restent solides à température ambiante — le beurre, la graisse de la viande rouge, l'huile de noix de coco et l'huile de palme., low fiber, high sodium, and inflammation interacting with microbial pathways ^[5,25]. The SWAP-MEAT crossover trial (n = 36; single-site, no washout period) illustrates the interpretive caution required: overall TMAO was lower during the plant-based-meat phase (2.7 vs 4.7 µmol/L, P = 0.012), but the trial was funded by a plant-based-meat manufacturer, and the effect was driven by a significant order effect (P = 0.023)—the difference appeared only in participants who consumed animal meat first (2.9 vs 6.4 µmol/L, P = 0.007) and not in those who consumed plant-based meat first (2.5 vs 3.0 µmol/L, P = 0.23). The trial did not—and with n = 36 was underpowered to—show that these transient TMAO shifts translate into differences in arterial inflammation or hard clinical events ^[22].

Systematic Evaluation Using the Bradford Hill Criteria

Table 3. Bradford Hill appraisal of circulating TMAO as a causal mediator of CVD.

Criterion	Application to TMAO and cardiovascular disease	Statut
Strength	Observational HRs of roughly 1.2–2.5 for events and mortality (e.g., NEJM HR 2.54 in a high-risk angiography cohort); modest in lower-risk settings and markedly attenuated after eGFR adjustment [3,10,11,16,17]	Weak–moderate
Consistency	Highly reproducible as an observational association across cohorts, but not corroborated as a causal effect in Mendelian randomisationLa randomisation est le processus qui consiste à assigner les participants à un essai à des groupes de traitement ou témoins par le hasard, garantissant ainsi que les facteurs de confusion connus et inconnus sont répartis de manière égale ; lorsque la randomisation échoue — comme l'ont constaté des auditeurs dans le cas de PREDIMED —, les groupes peuvent différer d'une manière qui fausse l'effet apparent du traitement. [3,10,11,12,13]	High for association; low across designs
Specificity	Elevated TMAO accompanies diabetes, NAFLD, obesity, CKD, and other conditions; not specific to vascular disease [7,18]	Unmet
Temporality	Prospective cohorts establish that elevated TMAO precedes events (temporal ordering met); bidirectional MR indicates this ordering is confounded by reverse causation from T2DM and CKD [3,13]	Met for ordering; confounded
Biological gradient	Dose-response reported for mortality and for blood pressure, but remains vulnerable to renal-function confounding [11,14]	Partially met
Plausibility	Coherent cellular pathways: scavenger-receptor upregulation, impaired reverse cholesterol transport, NF-κB/NLRP3NLRP3 est un système d'alarme présent à l'intérieur des cellules immunitaires. Lorsqu'il détecte quelque chose qu'il traite comme une menace, il déclenche une vague de signalisation inflammatoire. activation, platelet hyperreactivity [4,21]	Met (experimental)
Coherence	The fish paradox conflicts with a simple toxin model—seafood spikes TMAO yet is cardioprotective—though context-specific effects are not excluded [20]	Partially unmet
Experiment	Rodent feeding accelerates atherosclerosis; no human trial yet shows that lowering TMAO reduces events or vascular inflammation [2,29]	Partial (animal only)
Analogy	Resembles clearance-dependent markers (ADMA, cystatin C) reflecting kidney-heart crosstalk; analogy is hypothesis-generating, not causal evidence [15,17]	Weak / not probative

On balance, the observational association is strong and biologically plausible, but the criteria that bear most on causation—cross-design consistency, specificity, freedom from reverse-causation confounding, and coherence with the fish data—are only partially met or unmet. The framework therefore supports TMAO as a robust risk marker while falling short of establishing it as a primary causal driver of human ASCVD ^[13,20].

GRADE Certainty of Evidence

GRADE is best applied to discrete questions rather than to a single pooled judgment that mixes prognosis, génétiqueLa génétique est l'étude de ce que vous héritez de vos parents., animal mechanism, and diet responsiveness. The evidence is therefore separated into four distinct questions, each with its own certainty rating.

Table 4. GRADE summary by question.

Question	Finding	Certitude	Basis
Is TMAO a prognostic biomarker in high-risk cohorts?	Baseline TMAO predicts MACE, insuffisance cardiaqueL'insuffisance cardiaque signifie que le cœur ne pompe pas assez bien pour répondre aux besoins du corps. Ce nom est trompeur : cela ne signifie pas que le cœur s'est arrêté., and mortality in CAD, ACS, HF, and CKD populations [3,10,11,12]	Modéré	Large consistent cohorts with dose-response, downgraded for substantial confounding by renal function and disease severity [15,16,17]
Does TMAO causally drive human ASCVD events?	Genetically predicted TMAO/carnitine show no direct link to CAD, MI, stroke, AF, or T2DM; rodent feeding accelerates plaque [2,13]	Faible	Animal plausibility but no MR support for a large direct effect; rodent indirectness (no CETPCETP is a protein that swaps cholesterol and triglycerides between HDL and the harmful ApoB particles., different bile-acid handling, supraphysiological doses) [7,13]
Does lowering TMAO improve clinical outcomes?	TMA-lyase inhibitors lower TMAO and atherosclerosis in animals; no human outcome trial exists [21,29]	Très bas	No randomized human hard-outcome trial of selective TMAO lowering has been reported
Can diet meaningfully change circulating TMAO?	Red meat raises, and fiber-/plant-rich diets and antibiotic suppression lower, circulating TMAO [5,25]	Haut	Consistent high-quality randomized crossover and challenge studies showing rapid microbial plasticity [5,25]

Current state of the evidence at a glance

Synthesizing the above, the individual claims commonly grouped under the “TMAO hypothesis” sit at very different levels of certainty and should not be asserted with uniform confidence.

Table 6. Tiered summary of TMAO evidence, strongest to weakest.

Certainty tier	Claims supported at this level
Well established (high certainty)	TMAO predicts cardiovascular risk in high-risk cohorts; reduced renal function raises circulating TMAO; seafood raises TMAO; gut microbiota generate TMA from dietary precursors; diet meaningfully modifies TMAO
Moderate certainty	TMAO/FMO3 biology is linked to metabolic dysfunction; animal and cellular mechanisms for atherogenesis, thrombosis, and cholesterol handling are biologically plausible; a modest causal effect on systolic blood pressure is possible
Weak or conflicting	Circulating TMAO directly causes human atherosclerotic events; lowering TMAO reduces cardiovascular events; a defined human “toxic threshold” exists outside advanced CKD

Scientific Consensus and Remaining Controversies

Consensus has shifted from viewing TMAO as a simple vascular toxin to recognizing it as an integrative metabolic reporter sitting at the intersection of diet quality, microbiome composition, hepatic metabolism, and renal clearance ^[10,16]. As a prognostic tool, elevated TMAO usefully stratifies risk—particularly in established CAD, ACS, heart failure, and CKD—capturing kidney-heart-gut dysfunction not reflected in standard lipid, glycemic, or inflammatory panels ^[16,18,32]. Several controversies persist:

• Causality: despite plausibility and rodent pathogenicity, the absence of MR support plus the fish paradox lead many investigators to regard circulating TMAO as primarily a passenger at normal human concentrations ^[13,20].
• Therapeutic targeting: non-lethal TMA-lyase inhibitors (e.g., 3,3-dimethyl-1-butanol, iodomethylcholine) reduce TMAO, platelet hyperreactivity, and atherosclerosis in animals, but whether they lower human events is unknown; critics argue that suppressing a downstream marker without addressing diet, inactivity, and adiposity may not reduce events ^[29].
• The eGFR-adjustment question: some hold that adjusting for eGFR over-corrects because TMAO may itself contribute to renal decline (i.e., a mediator), while others insist that without rigorous adjustment for measured GFR or cystatin C the observational signal is confounded by subclinical kidney impairment ^[16,17].

These controversies map onto a genuine divergence in expert interpretation. The causal hypothesis has been advanced most vigorously by the Cleveland Clinic group whose experimental program produced much of the foundational work—the original phosphatidylcholine and L-carnitine pathway studies, the FMO3 and platelet-hyperreactivity mechanisms, and the TMA-lyase inhibitor proof-of-concept ^{[1,2,4,21,29]}—and which reads the convergent cohort and mechanistic data as evidence of a modifiable causal contributor. A more cautious reading, prominent among cardiovascular epidemiologists and nutrition researchers, emphasizes the null Mendelian randomization findings, the dominant role of renal clearance as a confounder, and the fish paradox, and treats TMAO as chiefly a marker of diet, microbiome, and kidney-heart crosstalk. The two positions are not as far apart as they appear: both accept the prognostic value and the microbial pathway, and disagree mainly on whether lowering circulating TMAO would alter human events—an empirical question that only a randomized outcome trial can settle ^[13,20,29].

In sum, TMAO remains a valuable biomarker for risk stratification and precision nutrition, but the current weight of genetic and epidemiological evidence argues against a primary causal role in human atherosclerotic disease ^[13]. Randomized trials of selective TMA-lyase inhibition will be needed to determine whether lowering circulating TMAO reduces events—assuming an agent proves safe for long-term human use, since all successful work to date remains preclinical—or whether clinical focus should remain on the fundamental drivers: diet quality, physical activity, insulin sensitivity, and renal health ^[13,29].

Limitations of the Current Evidence Base

Several constraints bound every conclusion above and are stated explicitly here rather than left implicit.

• Most human evidence is observational, and even large, well-adjusted cohorts cannot fully exclude residual confoundingThe bias that remains in an observational study even after statistical adjustment, because some shared risk factors — such as poverty, smoking, or diabetes — cannot be fully measured or removed; with a modest relative risk like 1.20, residual confounding alone could plausibly explain the entire observed association. by renal function, metabolic disease severity, and diet quality.
• Human intervention trials that lower TMAO and measure hard cardiovascular endpoints do not exist; the therapeutic question is therefore unresolved rather than settled negatively.
• Mendelian randomization has its own limitations—potential pleiotropy of metabolite-associated variants, instruments derived from relatively small exposure GWAS, and assumptions that cannot be fully verified—so null MR results argue against a large lifelong effect but do not exclude context-specific or acute effects.
• Animal and cellular models frequently require supraphysiological exposures and differ from humans in lipoprotein handling (e.g., absence of CETP) and bile-acid metabolism, limiting direct translation.
• TMAO assays and reference ranges are not fully standardized across laboratories, complicating cross-study comparison of absolute concentrations and any proposed thresholds.
• TMAO may exert different biological effects depending on concentration and clinical context—plausibly inert at physiological levels yet pathogenic at the supraphysiological concentrations of advanced CKD—so a single verdict across all populations is inappropriate.

Future Research Directions

The following questions would most efficiently move the field from association toward causal clarity:

• Do selective TMA-lyase inhibitors reduce major adverse cardiovascular events in adequately powered, long-term randomized human trials, and are they safe for chronic use?
• Is there a definable TMAO concentration threshold above which pathogenicity emerges, particularly across CKD stages?
• Are TMA and TMAO biologically distinct in their vascular and renal effects, and which is the more proximate mediator?
• Do common FMO3 genetic variants alter cardiovascular or renal risk in humans, providing a natural experiment for causal inference?
• Does TMAO have qualitatively different effects in advanced CKD versus preserved renal function, as the dual-nature model predicts?
• Can durable gut-microbiome manipulation (diet, prebiotics, or engineered consortia) sustainably lower TMAO, and does doing so improve vascular endpoints independent of concomitant LDL-C, blood-pressure, and weight changes?

Références

1. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57-63. doi:10.1038/nature09922
2. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576-585. doi:10.1038/nm.3145
3. Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575-1584. doi:10.1056/NEJMoa1109400
4. Koeth RA, Levison BS, Culley MK, et al. γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab. 2014;20(5):799-812. doi:10.1016/j.cmet.2014.10.006
5. Koeth RA, Lam-Galvez BR, Kirsop J, et al. l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. J Clin Invest. 2019;129(1):373-387. doi:10.1172/JCI94601
6. Bennett BJ, de Aguiar Vallim TQ, Wang Z, et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 2013;17(1):49-60. doi:10.1016/j.cmet.2012.12.011
7. Miao J, Ling AV, Manthena PV, et al. Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nat Commun. 2015;6:6498. Published 2015 Apr 7. doi:10.1038/ncomms7498
8. Shih DM, Wang Z, Lee R, et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res. 2015;56(1):22-37. doi:10.1194/jlr.M051680
9. Schugar RC, Shih DM, Warrier M, et al. The TMAO-Producing Enzyme Flavin-Containing Monooxygenase 3 Regulates Obesity and the Beiging of White Adipose Tissue. Cell Rep. 2017;19(12):2451-2461. doi:10.1016/j.celrep.2017.05.077
10. Qi J, You T, Li J, et al. Circulating trimethylamine N-oxide and the risk of cardiovascular diseases: a systematic review and meta-analysis of 11 prospective cohort studies. J Cell Mol Med. 2018;22(1):185-194. doi:10.1111/jcmm.13307
11. Schiattarella GG, Sannino A, Toscano E, et al. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. Eur Heart J. 2017;38(39):2948-2956. doi:10.1093/eurheartj/ehx342
12. Heianza Y, Ma W, Manson JE, Rexrode KM, Qi L. Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta-Analysis of Prospective Studies. J Am Heart Assoc. 2017;6(7):e004947. Published 2017 Jun 29. doi:10.1161/JAHA.116.004947
13. Jia J, Dou P, Gao M, et al. Assessment of Causal Direction Between Gut Microbiota-Dependent Metabolites and Cardiometabolic Health: A Bidirectional Mendelian Randomization Analysis. Diabetes. 2019;68(9):1747-1755. doi:10.2337/db19-0153
14. Wang H, Luo Q, Ding X, Chen L, Zhang Z. Trimethylamine N-oxide and its precursors in relation to blood pressure: A mendelian randomization study. Front Cardiovasc Med. 2022;9:922441. Published 2022 Jul 22. doi:10.3389/fcvm.2022.922441
15. Winther SA, Øllgaard JC, Tofte N, et al. Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. Diabetes Care. 2019;42(8):1512-1520. doi:10.2337/dc19-0048
16. Lee Y, Nemet I, Wang Z, et al. Longitudinal Plasma Measures of Trimethylamine N-Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community-Based Older Adults. J Am Heart Assoc. 2021;10(17):e020646. doi:10.1161/JAHA.120.020646
17. Gruppen EG, Garcia E, Connelly MA, et al. TMAO is Associated with Mortality: Impact of Modestly Impaired Renal Function. Sci Rep. 2017;7(1):13781. Published 2017 Oct 23. doi:10.1038/s41598-017-13739-9
18. Stubbs JR, House JA, Ocque AJ, et al. Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden. J Am Soc Nephrol. 2016;27(1):305-313. doi:10.1681/ASN.2014111063
19. Tang WH, Wang Z, Kennedy DJ, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116(3):448-455. doi:10.1161/CIRCRESAHA.116.305360
20. Velasquez MT, Ramezani A, Manal A, Raj DS. Trimethylamine N-Oxide: The Good, the Bad and the Unknown. Toxins (Basel). 2016;8(11):326. Published 2016 Nov 8. doi:10.3390/toxins8110326
21. Zhu W, Gregory JC, Org E, et al. Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk. Cell. 2016;165(1):111-124. doi:10.1016/j.cell.2016.02.011
22. Crimarco A, Springfield S, Petlura C, et al. A randomized crossover trial on the effect of plant-based compared with animal-based meat on trimethylamine-N-oxide and cardiovascular disease risk factors in generally healthy adults: Study With Appetizing Plantfood-Meat Eating Alternative Trial (SWAP-MEAT). Am J Clin Nutr. 2020;112(5):1188-1199. doi:10.1093/ajcn/nqaa203
23. Smits LP, Kootte RS, Levin E, et al. Effect of Vegan Fecal Microbiota Transplantation on Carnitine- and Choline-Derived Trimethylamine-N-Oxide Production and Vascular Inflammation in Patients With Metabolic Syndrome. J Am Heart Assoc. 2018;7(7):e008342. Published 2018 Mar 26. doi:10.1161/JAHA.117.008342
24. Wu WK, Chen CC, Liu PY, et al. Identification of TMAO-producer phenotype and host-diet-gut dysbiosis by carnitine challenge test in human and germ-free mice. Gut. 2019;68(8):1439-1449. doi:10.1136/gutjnl-2018-317155
25. Guasch-Ferré M, Satija A, Blondin SA, et al. Meta-Analysis of Randomized Controlled Trials of Red Meat Consumption in Comparison With Various Comparison Diets on Cardiovascular Risk Factors. Circulation. 2019;139(15):1828-1845. doi:10.1161/CIRCULATIONAHA.118.035225
26. O’Connor LE, Kim JE, Clark CM, Zhu W, Campbell WW. Effects of Total Red Meat Intake on Glycemic Control and Inflammatory Biomarkers: A Meta-Analysis of Randomized Controlled Trials. Adv Nutr. 2021;12(1):115-127. doi:10.1093/advances/nmaa096
27. Regis B, Passeri L, Moreira NX, Borges NA, Ribeiro-Alves M, Mafra D. Plasma Trimethylamine N-Oxide Levels in Nondialysis Chronic Kidney Disease Patients Following Meal Challenge. Mol Nutr Food Res. 2025;69(14):e70121. doi:10.1002/mnfr.70121
28. Zhang AQ, Mitchell SC, Smith RL. Dietary precursors of trimethylamine in man: a pilot study. Food Chem Toxicol. 1999;37(5):515-520. doi:10.1016/s0278-6915(99)00028-9
29. Wang Z, Roberts AB, Buffa JA, et al. Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis. Cell. 2015;163(7):1585-1595. doi:10.1016/j.cell.2015.11.055
30. Li Y, Lu H, Guo J, et al. Gut microbiota-derived trimethylamine N-oxide is associated with the risk of all-cause and cardiovascular mortality in patients with chronic kidney disease: a systematic review and dose-response meta-analysis. Ann Med. 2023;55(1):2215542. doi:10.1080/07853890.2023.2215542
31. Chen G, He L, Dou X, Liu T. Association of Trimethylamine-N-Oxide Levels with Risk of Cardiovascular Disease and Mortality among Elderly Subjects: A Systematic Review and Meta-Analysis. Cardiorenal Med. 2022;12(2):39-54. doi:10.1159/000520910
32. Senthong V, Wang Z, Li XS, et al. Intestinal Microbiota-Generated Metabolite Trimethylamine-N-Oxide and 5-Year Mortality Risk in Stable Coronary Artery Disease: The Contributory Role of Intestinal Microbiota in a COURAGE-Like Patient Cohort. J Am Heart Assoc. 2016;5(6):e002816. Published 2016 Jun 10. doi:10.1161/JAHA.115.002816